Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
EyePoint Begins Phase 3 LUCIA Trial for Wet AMD
EyePoint Pharmaceuticals has successfully dosed the first patient in the LUCIA trial, marking the start of the company’s second global Phase 3 clinical study for Duravyu (formerly EYP-1901), an investigational sustained-release therapy for wet age-related macular degeneration (wet AMD). Duravyu:…
ARPA-H Grants $125M for Eye Transplants
The Advanced Research Projects Agency for Health (ARPA-H) has announced funding of up to $125 million to support groundbreaking research into human eye transplantation. The funding, part of the Transplantation of Human Eye Allografts (THEA) program, aims to advance the…
Prevent Blindness Offers GA Educational Materials
Prevent Blindness, a leading nonprofit organization dedicated to eye health, has announced its fourth annual Geographic Atrophy (GA) Awareness Week, taking place from December 2–8, 2024. Geographic Atrophy, an advanced form of dry age-related macular degeneration (AMD), affects an estimated…
AI-Ready Dataset Released for Type 2 Diabetes Research
A groundbreaking study has unveiled a flagship dataset designed to explore the biomarkers and environmental influences that contribute to the development of type 2 diabetes (T2D). This comprehensive dataset includes data from participants ranging from healthy individuals to those at…
ONS-5010 Falls Short in NORSE EIGHT Trial for Wet AMD
ONS-5010 (LYTENAVA), an ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration (AMD), failed to meet the noninferiority endpoint in the NORSE EIGHT clinical trial, according to preliminary topline results announced by Outlook Therapeutics. About the NORSE EIGHT Trial…
Gene Editing Offers Hope for Retinitis Pigmentosa
Researchers funded by the National Eye Institute (NEI) have made significant strides in the treatment of retinitis pigmentosa (RP), a genetic disorder that causes progressive vision loss. Using a CRISPR-Cas9-based tool called base editing, the team corrected a specific mutation…
Avirmax Launches ABI-110 Gene Therapy Trial for Wet AMD
Avirmax Biopharma has reached a major milestone in its mission to revolutionize the treatment of wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) by successfully dosing the first patient in the phase I/IIa clinical trial of ABI-110, the…
NHS Launches OCT Scans for Diabetic Eye Care
The National Health Service (NHS) England is launching a nationwide program to make optical coherence tomography (OCT) scans more accessible, aiming to improve outcomes for patients with diabetic retinopathy. This initiative will bring advanced imaging technology closer to home for…
Ocular Pain in DED: Insights from the Tibetan Plateau
A recent Chinese study has shed light on the prevalence and influencing factors of ocular pain in individuals suffering from dry eye disease (DED) residing at high altitudes on the Tibetan Plateau. Co-authored by Peng-Cheng Zhang, MD, PhD, and Wen-Shan…
CHMP Endorses FYB203: Aflibercept Biosimilar Approval
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the marketing authorization of FYB203, a biosimilar candidate to aflibercept. This development marks a significant milestone in expanding affordable…